Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07093359

LINX vs Fundoplication

Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux symptoms. As an alternative, some surgeons use a device called LINX, using a keyhole procedure. LINX is a magnetic device that wraps around the lower oesophagus to prevent reflux. Studies suggest that LINX may cause fewer complications, with a similar improvement in quality-of-life. However, there is a need for better evidence to compare LINX with fundoplication in the surgical treatment of reflux disease. GOLF is a multi-centre study designed which to determine if LINX achieves similar reflux control and improves symptoms compared to fundoplication. GOLF measures: (1) quality of life,(2) surgical complications, including need for additional treatment, (3) financial cost-effectiveness and (4) objectively measure the presence of acid that has refluxed into the lower oesophagus. GOLF aims randomise 460 patients to receive fundoplication or the LINX device. It will be conducted across at least 16 UK and 7 European specialist surgical centres. All participants will be followed up at 6 weeks, 6, 12 and 24 months to assess which treatment offers the best results after surgery. A quality assurance programme within participating centres will ensure that procedures are completed to a high-quality standard. Study results will incorporate a patient and public involvement programme, which will inform national and international guidelines for the surgical treatment of reflux disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Guy's and St Thomas's NHS Foundation Trust, Guy's and St Thomas's Hospital, Oxford, Oxfordshire, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years and above
  • Willing and able to give informed consent
  • Patients with GORD insufficiently controlled by medical therapy or intolerance to medical therapy being considered for anti-reflux surgery
  • Symptomatic and objectively defined GORD; endoscopy with appearances or biopsies consistent with reflux oesophagitis, or 24-hour pH study or BRAVO test of the oesophagus consistent with GORD
  • No hiatal hernia or hiatal hernia <5 cm in length
  • Adequate lower oesophageal motility as defined by preoperative oesophageal manometry study. Oesophageal manometry will show a mean contractile amplitude of >30 mmHg or DCI >450 mmHg-s-cm in 70% of swallows.

Exclusion criteria

  • Unsuitable for surgical intervention due to medical conditions precluding general anaesthesia
  • Suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials
  • Previous anti-reflux or gastric surgery
  • Previous or planned neurosurgical intervention
  • Oesophageal manometry showing complete absence of lower oesophageal contractility

Treatment and study plan

Laparoscopic or robotic LINX procedure

Procedure

Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.

Laparoscopic or robotic fundoplication

Procedure

Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.

Primary outcomes

  1. Symptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire

    Time frame: 24 months following surgery

Secondary outcomes

  1. Prevalence of gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

    Time frame: 24 months postoperatively

  2. Prevalence of inability to belch measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

    Time frame: 24 months postoperatively

  3. Prevalence of symptomatic GORD, inability to belch and gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire

    Time frame: 6 weeks, 6 and 12 months after surgery

  4. Severity of dysphagia and regurgitation measured using participant-reported outcomes/GORD-HRQL questionnaire

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

  5. Global HRQL measured using participant-reported outcomes/EQ-5D-5L questionnaire

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

  6. Utilisation of anti-GORD medications measured using participant-reported outcomes/questionnaire

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

  7. 24-hour pH measurement measured using participant's medical records/24-hour pH measurement or BRAVO test

    Time frame: 12 months postoperatively

  8. Postoperative complication rates, including reoperation and endoscopic reintervention, measured using participant's medical records/postoperative outcomes

    Time frame: 30-day, 90-day, 12 and 24-month

  9. Cost-effectiveness of both treatments as measured by incremental cost per quality-adjusted life year (QALY)

    Time frame: 6 weeks, 6, 12 and 24 months postoperatively

Study contacts

Contact information is provided by the study sponsor or research team.

Sheraz Markar, PhD, FRCS, MSc, MA

CONTACT

[email protected]

+44 07584039433

Sponsors and collaborators

Lead sponsor

University of Oxford

Other

Collaborators

  • Guy's and St Thomas' NHS Foundation Trust
  • Imperial College London
  • King's College London
  • Oxford University Hospitals NHS Trust
  • University of Bristol
  • University of Southampton

Registry information

Official study title

Double-blind Randomised Controlled Trial for Treatment of Gastro-Oesophageal Reflux Disease; LINX Management System vs. Fundoplication (GOLF)

Acronym: GOLF

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Jul 30, 2025
Registry last updated
Aug 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.